SEC Company Response from Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306) (TNXP) — Jul 9, 2019
Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306)
Date: July 9, 2019 · CIK: 0001430306 · Accession: 0001387131-19-004919
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232195
Letter
Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue, Suite 1608
New York, New York 10022
July 9, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Re: Tonix Pharmaceuticals Holding Corp. Registration Statement on Form S-1 (File No. 333-232195)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Tonix Pharmaceuticals Holding Corp. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at 4:30 p.m., Eastern Standard Time, on July 11, 2019, or as soon as practicable thereafter.
Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.
[Signature page follows.]
U.S. Securities and Exchange Commission
July 9, 2019
Page 2
Very truly yours,
TONIX PHARMACEUTICALS
Show Raw Text
CORRESP
1
filename1.htm
Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue, Suite 1608
New York, New York 10022
July
9, 2019
VIA
EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Re: Tonix
Pharmaceuticals Holding Corp.
Registration Statement on Form S-1 (File No. 333-232195)
Ladies
and Gentlemen:
In
accordance with Rule 461 under the Securities Act of 1933, as amended, Tonix Pharmaceuticals Holding Corp. (the “Company”)
hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared
effective by the Securities and Exchange Commission (the “Commission”) at 4:30 p.m., Eastern Standard Time,
on July 11, 2019, or as soon as practicable thereafter.
Please
call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement
or with any questions.
[Signature
page follows.]
U.S.
Securities and Exchange Commission
July 9, 2019
Page 2
Very truly yours,
TONIX PHARMACEUTICALS
HOLDINGS CORP.
By:
/s/ Bradley Saenger
Name:
Title:
Bradley Saenger
Chief Financial Officer